Get our newsletters

Business briefs: June 23, 2022


Greater Philadelphia banking leader Robert “Bob” Kane, Jr. has announced his retirement from KeyBank effective July 1, after a distinguished career in commercial banking that has spanned more than four decades.

He will be succeeded by KeyBank Commercial Sales Leader Jamie Tranfalia, who will be named market president upon Kane’s retirement.

Tranfalia joined Key in December 2021 as commercial sales leader reporting to Kane. He is an experienced commercial banking leader with more than 22 years of experience in the financial services industry.

Tranfalia is a military veteran, serving for several years as a U.S. Air Force captain and Nuclear Missile Crew commander. He earned his bachelor’s degree in biology from the U.S. Air Force Academy and MBA from Colorado State University. He is an active member of the community.

Three attorneys from Williams Family Law in Doylestown have been named to the 2022 Pennsylvania Super Lawyers list, a research-driven, peer-influenced rating system that recognizes attorneys who consistently hold themselves to the highest professional standards.

Founder and Managing Partner Jeffrey M. Williams and partner Susan J. Smith were selected as Super Lawyers, and associate Shauna Quigley was named a Rising Star.

Part of Thomson Reuters, Super Lawyers is a rating service of outstanding lawyers from more than 70 practice areas who have attained a high degree of peer recognition and professional achievement. The Rising Stars list is open to attorneys aged 40 or younger or in practice less than 10 years.

Williams has been listed annually on the Pennsylvania Super Lawyers list since 2005. Smith has been named to the Super Lawyers several times since 2005. Quigley has been named to the Rising Star list annually since 2018.

ImmunOs Therapeutics AG, a Schlieren (Zurich Area), Switzerland, and Gaithersburg, Md., based biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, announced the closing June 7, of an oversubscribed Series B financing round totaling $74 million.

The round was led by new investors Samsara BioCapital, Lightspeed Venture Partners, and Gimv, and joined by new investors Mission BioCapital, GL Capital, PEAK6 Strategic Capital, and Fiscus Financial, as well as existing investors Pfizer Ventures, BioMed Partners, and Schroder Adveq.

Sean R. Smith, a graduate of Central Bucks High School East in the 1990s, is CEO of ImmunOs.

The proceeds of the Series B will be used to fund the clinical development of ImmunOs’ lead program, IOS-1002 (formerly iosH2), through Phase 2 clinical trials and to progress additional oncology and autoimmune disease programs within the company´s HLA-based pipeline toward clinical development.

A Phase 1 clinical trial is planned to start in the second half of 2022.

ImmunOs has established a U.S. subsidiary to further expand its international reach, execute future U.S. clinical trials, and strengthen its transatlantic operations and team.